JP2022532139A5 - - Google Patents

Info

Publication number
JP2022532139A5
JP2022532139A5 JP2021566276A JP2021566276A JP2022532139A5 JP 2022532139 A5 JP2022532139 A5 JP 2022532139A5 JP 2021566276 A JP2021566276 A JP 2021566276A JP 2021566276 A JP2021566276 A JP 2021566276A JP 2022532139 A5 JP2022532139 A5 JP 2022532139A5
Authority
JP
Japan
Prior art keywords
hbv
tada
gene
nucleic acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021566276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532139A (ja
JP7679309B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032226 external-priority patent/WO2020231863A1/en
Publication of JP2022532139A publication Critical patent/JP2022532139A/ja
Publication of JP2022532139A5 publication Critical patent/JP2022532139A5/ja
Priority to JP2025033734A priority Critical patent/JP2025102768A/ja
Application granted granted Critical
Publication of JP7679309B2 publication Critical patent/JP7679309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021566276A 2019-05-10 2020-05-08 B型肝炎を治療するための組成物及び方法 Active JP7679309B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025033734A JP2025102768A (ja) 2019-05-10 2025-03-04 B型肝炎を治療するための組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962846422P 2019-05-10 2019-05-10
US62/846,422 2019-05-10
US201962927585P 2019-10-29 2019-10-29
US62/927,585 2019-10-29
PCT/US2020/032226 WO2020231863A1 (en) 2019-05-10 2020-05-08 Compositions and methods for treating hepatitis b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025033734A Division JP2025102768A (ja) 2019-05-10 2025-03-04 B型肝炎を治療するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022532139A JP2022532139A (ja) 2022-07-13
JP2022532139A5 true JP2022532139A5 (cg-RX-API-DMAC7.html) 2023-05-16
JP7679309B2 JP7679309B2 (ja) 2025-05-19

Family

ID=73289231

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566276A Active JP7679309B2 (ja) 2019-05-10 2020-05-08 B型肝炎を治療するための組成物及び方法
JP2025033734A Pending JP2025102768A (ja) 2019-05-10 2025-03-04 B型肝炎を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025033734A Pending JP2025102768A (ja) 2019-05-10 2025-03-04 B型肝炎を治療するための組成物及び方法

Country Status (8)

Country Link
US (1) US20230070861A1 (cg-RX-API-DMAC7.html)
EP (1) EP3965832A4 (cg-RX-API-DMAC7.html)
JP (2) JP7679309B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220019685A (cg-RX-API-DMAC7.html)
CN (2) CN114929287B (cg-RX-API-DMAC7.html)
AU (1) AU2020276218A1 (cg-RX-API-DMAC7.html)
CA (1) CA3139324A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020231863A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
WO2021222318A1 (en) 2020-04-28 2021-11-04 The Broad Institute, Inc. Targeted base editing of the ush2a gene
AU2022216614B2 (en) 2021-02-05 2026-03-05 Christiana Care Gene Editing Institute, Inc. Methods of and compositions for reducing gene expression and/or activity
EP4301395A4 (en) * 2021-03-12 2025-06-18 Massachusetts Institute of Technology COMPOSITIONS AND METHODS FOR DOMINANT ANTIVIRAL THERAPY
AU2022315298A1 (en) * 2021-07-22 2024-02-22 Emendobio Inc. Hepatitis b virus (hbv) knockouts
KR20240111821A (ko) * 2021-09-27 2024-07-17 빔 테라퓨틱스, 인크. B형 간염 바이러스 감염을 치료하기 위한 조성물 및 방법
WO2024103050A1 (en) * 2022-11-11 2024-05-16 The United States Government As Represented By The Department Of Veterans Affairs Hbv specific exosomes and uses thereof
WO2024186890A1 (en) * 2023-03-06 2024-09-12 Intellia Therapeutics, Inc. Compositions and methods for hepatitis b virus (hbv) genome editing
JP2026523341A (ja) 2023-05-15 2026-07-14 エヌクロマ・バイオ,インコーポレーテッド Hbv遺伝子発現のエピジェネティック調節のための組成物および方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6738728B2 (ja) * 2013-06-17 2020-08-19 ザ・ブロード・インスティテュート・インコーポレイテッド 肝臓ターゲティングおよび治療のためのCRISPR−Cas系、ベクターおよび組成物の送達および使用
CN105899658B (zh) 2013-12-12 2020-02-18 布罗德研究所有限公司 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
CA3001351A1 (en) * 2015-10-21 2017-04-27 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating hepatitis b virus
WO2018027078A1 (en) * 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
EP3565608A4 (en) * 2017-01-05 2020-12-16 Rutgers, The State University of New Jersey TARGETED GENE EDITING PLATFORM INDEPENDENT OF BICATENARY DNA BREAKAGE AND ITS USES
WO2018237369A2 (en) * 2017-06-23 2018-12-27 Vical Incorporated Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection
WO2019005886A1 (en) * 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
EP3658573A1 (en) * 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
RU2652899C1 (ru) * 2017-12-28 2018-05-03 Федеральное бюджетное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) РНК-проводники для подавления репликации вируса гепатита B и для элиминации вируса гепатита B из клетки-хозяина

Similar Documents

Publication Publication Date Title
JP2025102768A5 (cg-RX-API-DMAC7.html)
US11913040B2 (en) Evolution of TALENs
JP2022546608A5 (cg-RX-API-DMAC7.html)
CN112601816B (zh) 使用可编程碱基编辑器系统遏止病原性突变的方法
US20240209338A1 (en) Evolution of cytidine deaminases
AU2019265019B2 (en) Methods of substituting pathogenic amino acids using programmable base editor systems
JP2025170240A5 (cg-RX-API-DMAC7.html)
JP2025120176A5 (cg-RX-API-DMAC7.html)
CN105934516B (zh) 用于基因编辑的cas变体
JP2022533673A5 (cg-RX-API-DMAC7.html)
JP2022545950A5 (cg-RX-API-DMAC7.html)
JP2021523738A5 (cg-RX-API-DMAC7.html)
JP2022124487A (ja) 遺伝子編集のための進化したCas9蛋白質
KR102515049B1 (ko) Cas9 변이체 및 그의 용도
EP3004349B1 (en) A method for producing precise dna cleavage using cas9 nickase activity
RU2260055C2 (ru) Способ амплификации днк и композиция для его осуществления
JP2021523736A5 (cg-RX-API-DMAC7.html)
EP3790595A1 (en) Methods of editing single nucleotide polymorphism using programmable base editor systems
JP2023545497A5 (cg-RX-API-DMAC7.html)
JP2024511621A5 (cg-RX-API-DMAC7.html)
JP2024534639A5 (cg-RX-API-DMAC7.html)
CN119013394A (zh) 用于治疗乙型肝炎病毒感染的组合物和方法
US20200224194A1 (en) Expression systems that facilitate nucleic acid delivery and methods of use
WO2022129905A1 (en) Crispr polypeptides
CN118726309A (zh) 基于微型CRISPR Cas蛋白Cas12f1的碱基编辑器系统及其应用